Association of atrial myopathy in mitral valve disease on safety outcomes in left atrial appendage closure

[1] Chugh SS(2014)Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation 129 837-847

[2] Schnabel RB(2015)50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study Lancet 386 154-162

[3] Piccini JP(2014)Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial Eur Heart J 35 1873-1880

[4] Hindricks G(2020)ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) Eur Heart J 70 2964-2975

[5] Reddy Vivek Y(2017)5-Year outcomes after left atrial appendage closure J Am Coll Cardiol 136 1588-1597

[6] Magnussen C(2017)Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe) Circulation 14 e010300-560

[7] Gertz ZM(2021)Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT Trial Circ Cardiovasc Interv 20 553-279

[8] Modena MG(1997)Left atrial size is the major predictor of cardiac death and overall clinical outcome in patients with dilated cardiomyopathy: a long-term follow-up study Clin Cardiol 94 274-592

[9] Lane CE(2019)An under-recognized high-risk atrial fibrillation population: analyzing transcatheter mitral valve repair patients for left atrial appendage closure device application Catheter Cardiovasc Interv 14 590-20

[10] Eleid MF(2021)Combined procedure of percutaneous mitral valve repair and left atrial appendage occlusion: a multicenter study Cardiovasc Interv 110 12-184

[1] Chugh SS(2014)Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation 129 837-847

[2] Schnabel RB(2015)50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study Lancet 386 154-162

[3] Piccini JP(2014)Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial Eur Heart J 35 1873-1880

[4] Hindricks G(2020)ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) Eur Heart J 70 2964-2975

[5] Reddy Vivek Y(2017)5-Year outcomes after left atrial appendage closure J Am Coll Cardiol 136 1588-1597

[6] Magnussen C(2017)Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe) Circulation 14 e010300-560

[7] Gertz ZM(2021)Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT Trial Circ Cardiovasc Interv 20 553-279

[8] Modena MG(1997)Left atrial size is the major predictor of cardiac death and overall clinical outcome in patients with dilated cardiomyopathy: a long-term follow-up study Clin Cardiol 94 274-592

[9] Lane CE(2019)An under-recognized high-risk atrial fibrillation population: analyzing transcatheter mitral valve repair patients for left atrial appendage closure device application Catheter Cardiovasc Interv 14 590-20

[10] Eleid MF(2021)Combined procedure of percutaneous mitral valve repair and left atrial appendage occlusion: a multicenter study Cardiovasc Interv 110 12-184